Regeno blend

PRODUCT KNOWLEDGE · BioLongevity Labs

A three-component listing with BPC-157, a TB-500-labeled component, and Cartalax in equal declared masses.

Listing checked October 4, 2026 · Original AI-assisted notes · Not reviewed by a medical professional

DECLARED COMPOSITION

30 mg total

3 ingredients

BPC-15710 mg
TB-500 label · full-length description10 mg
Cartalax10 mg

Seller-declared ingredient masses. Bar widths show mass proportions, not potency, molecular structure, or an administration schedule.

What the supplier lists

Seller describes a lyophilized vial. The composition below is attributed to this listing; it is not an independent measurement.

Declared composition · BioLongevity Labs · October 4, 2026
Listed ingredient	Declared amount	Identity & research context
BPC-157	10 mg	Named ingredient; batch identity not independently verified. BPC-157 research context →
TB-500 label · full-length description	10 mg	Seller describes a 43-residue thymosin beta-4 sequence, distinct from the seven-residue fragment. Thymosin beta-4 research context → TB-500 research context →
Cartalax	10 mg	Seller identifies the AED tripeptide. A dedicated source-reviewed PepsRadar profile is pending. Dedicated research profile pending

Composition source: Supplier composition and product description ↗ (affiliate link). A shared blend name can refer to different ingredients, ratios, or identities at another supplier.

Identity check

The seller's TB-500 description gives full-length thymosin beta-4. Cartalax is a separate listed ingredient, and no research profile is inferred from its marketing name.

Based on Supplier composition and product description ↗ (affiliate link); batch composition has not been independently verified.

Ingredient research and blend evidence

These are selected studies of individual ingredients or related identities. They did not validate the seller's finished blend. Open the linked profile for the population, design, results, and limitations.

INGREDIENT / RELATED IDENTITY

Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.

Rat tendon-cell study · 2014

Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.

Read profile evidence → · Original publication ↗

INGREDIENT / RELATED IDENTITY

Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015

Human randomized trial · 2015

Did ophthalmic treatment meet the primary dry-eye endpoints?

Read profile evidence → · Original publication ↗

INGREDIENT / RELATED IDENTITY

Biological activities of thymosin beta4 defined by active sites in short peptide sequences.

Related-peptide mechanistic review · 2010

Biological activities of thymosin beta4 defined by active sites in short peptide sequences.

Read profile evidence → · Original publication ↗

Questions an exact-formulation study would need to answer

Were the same chemical identities and ratio actually tested?
Was the preparation stable and compatible under the tested conditions?
Did the full combination improve a measured outcome against an appropriate comparator?
What adverse effects and interactions were measured, in which population and for how long?

Different ingredients or plausible mechanisms do not establish synergy. A research-use designation is not a finding of clinical safety or efficacy.

Supplier listing and documentation

Supplier: BioLongevity Labs
Listed starting price: $279.97
Snapshot availability: Listed in stock
Price check: 2026-10-04

Price and availability are dated listing snapshots. Shipping, taxes, options, and later changes are excluded.

Supplier composition and product description ↗ (affiliate link)

Direct link · No affiliate commission active. Listing inclusion does not verify the product or endorse the supplier.

Explore supplier documents →

A product description or general purity claim does not verify every ingredient or ratio in a purchased lot. Match the lot identifier, analytes, methods, and quantitative results to the specific material; a certificate does not establish a clinical outcome.

Continue researching

BPC-157 →Thymosin beta-4 →TB-500 →

Browse product knowledge → · Browse supplier catalog →

Educational product reference. No dosing, mixing, or administration instructions are provided. Medical and full-formulation evidence review remain pending.